View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 4, 2022

Roche obtains US FDA priority review for Covid-19 treatment

The sBLA submission is based on encouraging data from four trials of Actemra/RoActemra in over 5,500 Covid-19 patients.

Roche has obtained the US Food and Drug Administration (FDA) priority review for its supplemental Biologics License Application (sBLA) for intravenous Actemra/RoActemra (tocilizumab) to treat Covid-19.

A humanised interleukin-6 (IL-6) receptor antagonist, Actemra/RoActemra is currently approved to treat moderately to severely active rheumatoid arthritis (RA) in adults.

The treatment is intended for hospitalised Covid-19 adult patients who are taking systemic corticosteroids and need supplemental oxygen.

These patients also require non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.

Roche anticipates a decision on approval from the regulatory agency in the second half of this year.

The submission of the application was based on findings from four controlled, randomised clinical trials that assessed Actemra/RoActemra to treat Covid-19 in over 5,500 patients in the hospital.

Data from the EMPACTA, COVACTA, REMDACTA and RECOVERY trials suggest that the treatment could boost outcomes in subjects who are taking corticosteroids and need supplemental oxygen or breathing support.

In June last year, the FDA granted Emergency Use Authorization for Actemra/RoActemra, which is also approved in 16 countries globally for severe or critical Covid-19 patients in the hospital.

Earlier, Actemra/RoActemra obtained World Health Organization (WHO) prequalification in February this year for use in severe or critical Covid-19 patients, facilitating its access in low- and middle-income nations.

Roche Global Product Development chief medical officer and head Levi Garraway said: “The high rate of unvaccinated people will continue to put a strain on hospitals and healthcare systems around the world, furthering the need for effective treatments for patients hospitalised with Covid-19.

“More than one million people with severe or critical Covid-19 have already been treated with Actemra/RoActemra worldwide, demonstrating the important role of this medicine in the fight against the pandemic.”

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU